Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma

Forat Lutfi, MD, Ankit Kansagra, MD, Moaath Mustafa Ali, MD, Ali Bukhari, MD, Jonathan Siglin, BS, Jingsheng Yan, PhD, Santanu Samanta, MD, Noa G. Holtzman, MD, David Gottlieb, MD, Dong Won Kim, MD, Seung-Tae Lee, MD PhD, Mehmet Hakan Kocoglu, MD, Jean A. Yared, MD, Nancy M. Hardy, MD, Jason Molitoris, MD, Pranshu Mohindra, MD, Aaron P. Rapoport, MD, Saurabh Dahiya, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-141231

Published: 2020

Journal Articles

Low Utility of the H-Score and HLH-2004 Criteria to Identify Patients with Secondary Hemophagocytic Lymphohistiocytosis after CAR-T Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Dong Won Kim, MD, Forat Lutfi, MD, Facundo Zafforoni, BS, Moaath Mustafa Ali, MD MPH, Ali Bukhari, MD, David Gottlieb, MD, Seung-Tae Lee, MD PhD, Mehmet Hakan Kocoglu, MD, Nancy M. Hardy, MD, Jean A. Yared, MD, Aaron P. Rapoport, MD, Jennie Y. Law, MD, Saurabh Dahiya, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-141992

Published: 2020

Journal Articles

Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Christopher Melani, MD, Rahul Lakhotia, MD, Stefania Pittaluga, MD PhD, Milos D. Miljkovic, MDMSc, James D. Phelan, PhD, Jagan R. Muppidi, MD PhD, Craig J. Thomas, PhD, Michele Ceribelli, PhD, Frances Anne Tosto, MS, Craig A. Portell, MD, Rafic J. Farah, MD, Seung Tae Lee, MD PhD, Anna Marie Juanitez, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Mark Roschewski, MD, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-141447

Published: 2020

Journal Articles

A Phase I Study Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

William G. Wierda, MD PhD, Seung Tae Lee, MD PhD, Rong Chen, PhD, Daniella Zheleva, PhD, David Blake, PhD, Judy H Chiao, MD, William Plunkett, PhD

Blood (2019) 134 (Supplement_1): 1761.

https://doi.org/10.1182/blood-2019-128956

Published: 2019

Journal Articles

Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Christopher Melani, MD, Rahul Lakhotia, MD, Stefania Pittaluga, MD PhD, Milos D. Miljkovic, MDMSc, Jagan R. Muppidi, MD PhD, Craig A. Portell, MD, Rafic Farah, MD, Seung Tae Lee, MD PhD, Anna Marie Juanitez, RN, Lydia L. Chou, CRNP, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Louis Staudt, MD, Mark Roschewski, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 2867.

https://doi.org/10.1182/blood-2019-125990

Published: 2019

Journal Articles

Increased Cortical Glycolysis Following CD19 CART Therapy: A Radiographic Surrogate for an Altered Blood-Brain Barrier

Ali Bukhari, MD, Vivek Kesari, MD, Reza Sirous, MD, Noa G. Holtzman, MD, Seung Tae Lee, MD PhD, Natalie Gahres, RN, Elizabeth Hutnick, RN, Kathleen Ruehle, RN, Mehmet Hakan Kocoglu, MD, Ashraf Z. Badros, Jean A. Yared, MD, Nancy M. Hardy, MD, Aaron P. Rapoport, Babak Saboury, MD MPH, Saurabh Dahiya, MD

Blood (2019) 134 (Supplement_1): 4454.

https://doi.org/10.1182/blood-2019-125794

Published: 2019

Journal Articles

Indoximod Combined with Standard Induction Chemotherapy Is Well Tolerated and Induces a High Rate of Complete Remission with MRD-Negativity in Patients with Newly Diagnosed AML: Results from a Phase 1 Trial

Ashkan Emadi, MD PhD, Vu H. Duong, MD, Jeremy Pantin, MD, Mohammad Imran, MD, Rima Koka, MD PhD, Zeba Singh, MBBS, Edward A. Sausville, MD PhD, Jennie Y. Law, MD, Seung Tae Lee, MD PhD, Huidong Shi, PhD, Ravindra Kolhe, MD PhD, Maria R. Baer, MD, Michael R. Loken, PhD, Eugene P. Kennedy, MD, Charles Link, MD, David H. Munn, MD

Blood (2018) 132 (Supplement 1): 332.

https://doi.org/10.1182/blood-2018-99-117433

Published: 2018

Journal Articles

Reduction of Immunosuppression Does Not Significantly Impact Incidence of Renal Transplant Graft Rejection Following a Diagnosis of Post-Transplant Lymphoproliferative Disorder

Emily K Fay, MD, Abdolreza Haririan, MD MPH, Arnob Banerjee, MDPhD, Seung-Tae Lee, MD PhD, Jennie Y Law, MD

Blood (2017) 130 (Supplement 1): 5216.

https://doi.org/10.1182/blood.V130.Suppl_1.5216.5216

Published: 2017

Journal Articles

R-Bendamustine Vs R-CHOP As Initial Treatment for Advanced Stage Low Grade Follicular Lymphoma: A Matched-Pair Analysis

Blood (2014) 124 (21): 3048.

https://doi.org/10.1182/blood.V124.21.3048.3048

Published: 2014

Journal Articles

Intratumoral and Peripheral Blood T Cells Recognize Mutated Neo-Antigens in Follicular Lymphoma

Seung Tae Lee, MD PhD, Elena Percivalle, PhD, Xiaoyun Cheng, Greg Lizee, PhD, Nathan Fowler, MD, R Eric Davis, MD, Sattva S Neelapu, MD

Blood (2014) 124 (21): 809.

https://doi.org/10.1182/blood.V124.21.809.809

Published: 2014

Journal Articles

Antibiotic Therapy of H. Pylori Negative Gastric MALT Lymphoma

Seung Tae Lee, MD PhD, Purnima Teegavarupu, MD, Anusha Karri, Saswatha Anireddy, Fredrick B. Hagemeister, MD, Jorge E. Romaguera, MD, Luis Fayad, MD, Maria A. Rodriguez, MD, Felipe Samaniego, MD, Nathan Fowler, MD, Yasuhiro Oki, MD, Francesco Turturro, MD, Jason R. Westin, MD, Larry W Kwak, MD PhD, Bouthaina S. Dabaja, MD, Lei Feng, MS, R Eric Davis, MD, Sattva S Neelapu, MD

Blood (2014) 124 (21): 1735.

https://doi.org/10.1182/blood.V124.21.1735.1735

Published: 2014

Journal Articles

Extended Study for Topotecan, Idarubicin, and Intermediate-Dose Cytarabine Combination Chemotherapy in Patients with Refractory or Relapsed Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome.

Yuri Kim, MD, June-Won Cheong, MD, Jin Seok Kim, MD, PhD, In Hae Park, MD, Sun Young Park, MD, Seung Tae Lee, MD, PhD, Yoo-Hong Min, MD, PhD

Blood (2005) 106 (11): 4609.

https://doi.org/10.1182/blood.V106.11.4609.4609

Published: 2005

NARROW

The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma

Low Utility of the H-Score and HLH-2004 Criteria to Identify Patients with Secondary Hemophagocytic Lymphohistiocytosis after CAR-T Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

A Phase I Study Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Increased Cortical Glycolysis Following CD19 CART Therapy: A Radiographic Surrogate for an Altered Blood-Brain Barrier

Indoximod Combined with Standard Induction Chemotherapy Is Well Tolerated and Induces a High Rate of Complete Remission with MRD-Negativity in Patients with Newly Diagnosed AML: Results from a Phase 1 Trial

Reduction of Immunosuppression Does Not Significantly Impact Incidence of Renal Transplant Graft Rejection Following a Diagnosis of Post-Transplant Lymphoproliferative Disorder

R-Bendamustine Vs R-CHOP As Initial Treatment for Advanced Stage Low Grade Follicular Lymphoma: A Matched-Pair Analysis

Intratumoral and Peripheral Blood T Cells Recognize Mutated Neo-Antigens in Follicular Lymphoma

Antibiotic Therapy of H. Pylori Negative Gastric MALT Lymphoma

Extended Study for Topotecan, Idarubicin, and Intermediate-Dose Cytarabine Combination Chemotherapy in Patients with Refractory or Relapsed Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only